Efficacy and safety of pegylated interferon alfa-2b in moderate COVID-19: A phase II, randomized, controlled, open-label study - Pandit, Anuja; Bhalani, Nirav; Bhushan, B.L. Shashi; Koradia, Parshottam; Gargiya, Shweta; Bhomia, Vinay; Kansagra, Kevinkumar (International journal of infectious diseases, 2021)
Keywords: Adult; Aged; Antiviral; Antiviral Agents - therapeutic use; Coronavirus; COVID-19; COVID-19 - drug therapy; Female; Humans; Interferon alpha-2 - adverse effects; Interferon alpha-2 - therapeutic use; Interferon-alpha - adverse effects; Interferon-alpha - therapeutic use; Male; Middle Aged; Pegylated interferon alfa-2b (PEG IFN-α2b); Polyethylene Glycols - adverse effects; Polyethylene Glycols - therapeutic use; Recombinant Proteins - adverse effects; Recombinant Proteins - therapeutic use; SARS-CoV-2; COVID-19; Antiviral; Coronavirus; Pegylated interferon alfa-2b (PEG IFN-α2b)